RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.
RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancers, including colorectal and gastric cancer.
Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.
Rgenix CEO Masoud Tavazoie Discusses Immune System Regulation in Cancer at Plenary Session during AACR Meeting
On November 28, 2018, Masoud Tavazoie, Co-Founder and CEO of Rgenix, made a presentation at AACR’s Tumor Immunology and
New York, NY – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics,